<DOC>
	<DOCNO>NCT02058420</DOCNO>
	<brief_summary>Osteoporosis ( severe bone loss ) bone disease bone fragility increase chance bone fracture . Women 4 time likely osteoporosis men estrogen protection menopause woman general lighter thinner bone . Recent study indicate tocotrienols ( one kind vitamin E ) supplement may good bone health postmenopausal woman . However , study ever do role tocotrienols bone health postmenopausal woman . Our long-term goal develop new strategy feature dietary supplement ( i.e. , tocotrienols ) slow bone loss postmenopausal woman . The purpose study examine effect 12-week tocotrienols bone measurement postmenopausal woman . Investigators plan recruit postmenopausal woman use flyer , non-solicited e-mail system , campus announcement , local radio , newspaper , TV script . We plan enroll approximately 200 woman obtain 78 qualified woman start study . After screen , qualified participant match body weight age , randomly assign tocotrienols , low tocotrienols , high tocotrienols group . The outcome measure assess baseline , 6 , 12 week . Bone-related measurement record use blood urine sample . Investigators monitor safety subject 6 12 week . Food intake , physical activity , quality life assess baseline 12 week . All data analyze statistically .</brief_summary>
	<brief_title>Tocotrienols Bone Health Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<criteria>Inclusion criterion 1 . Postmenopausal woman menses 110 year . 2 . Bone mass bone mineral density ( BMD ) Tscore 0.5 2.5 spine and/or hip . 3 . Normal laboratory evaluation , thyroid function : TSH &gt; 0.3 &lt; 5.0 mU/L ; hepatic function : bilirubin ≤ 2.0 mg/dl ; SGOT ( also call AST ) /SGPT ( also call ALT ) &lt; 3x upper limit normal ; renal function : serum creatinine ≤ 2.0 mg/dl ; BUN le 1.5 time upper limit normal ; serum calcium , phosphorus , alkaline phosphatase : within normal range . HbA1c &lt; 7.0 % . 4 . Serum 25OH vitamin D &gt; = 20 ng/mL . 5 . Age 40 old Exclusion criterion 1 . History , evidence , metabolic bone disease include recent fracture ( low BMD ) . 2 . Having receive medication ( calcitonin , raloxifene , systemic glucocorticoid ) within 3 month start study . 3 . Having bisphosphonate within 12 month start study . 4 . Having hormone/hormonelike replacement therapy within 3 month initiation study . 5 . History cancer except treat superficial basal squamous cell carcinoma skin . 6 . History evidence endocrine disease malabsorption syndrome would contraindication investigation tocotrienols ' absorption . 7 . Uncontrolled diabetes mellitus define HbA1c ≥ 7 % last 3 month . 8 . History statin drug cholesterolcontrol within 3 month start study . 9 . Alcohol intake great `` moderate '' ( one drink per day ) use nonsteroidal antiinflammatory drug regular basis . 10 . Cognitive impairment , depression medical/eating disorder , likely move trial , lack transportation , distance study site , unavailable sample collection time . 11 . Smoking &gt; 10 cigarettes/day . 12 . Unwilling accept randomization .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>bone health</keyword>
</DOC>